Adequate clinical control of congenital nephrotic syndrome by enalapril.
The combination of captopril and indomethacin has been shown to control nephrotic proteinuria in an infant with congenital nephrotic syndrome of the Finnish type. We report the satisfactory control of congenital nephrotic syndrome by enalapril, maintaining normal serum albumin levels without albumin infusions. The haplotype data of our patient were consistent with the diagnosis of a Finnish-type nephrotic syndrome. After 21 months, during which daily infusions of albumin allowed partial control of the symptoms, captopril treatment was started. No adverse effects were noted. Serum creatinine levels remained normal. Within 8 weeks, albumin infusions were completely stopped. After 1 month the treatment was changed to a single dose of enalapril (0.8 mg/kg per day). During the next 15 months, the serum protein concentration was maintained around 6.5-7 g/dl, although proteinuria persisted (0.3-0.5 g/day). Weight and length gain are now satisfactory. We conclude that enalapril may be safely used in infants with severe forms of congenital nephrotic syndrome and might allow the avoidance of aggressive treatments for prolonged periods.
Guez
S
S
Department of Pediatrics, University of Milan, Italy.
Giani
M
M
Melzi
M L
ML
Antignac
C
C
Assael
B M
BM
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D002675:Child, Preschool; D004656:Enalapril / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005387:Finland; D005500:Follow-Up Studies; D006239:Haplotypes; D006801:Humans; D008967:Molecular Biology; D009404:Nephrotic Syndrome / Q000151:congenital* / Q000188:drug therapy* / Q000235:genetics; D011507:Proteinuria / Q000188:drug therapy
D000806:Angiotensin-Converting Enzyme Inhibitors; D004656:Enalapril